Home » Topics » Regulatory » EMA

EMA
RSS

EMA grants orphan designation to BHR Pharma's investigational agent for traumatic brain injury

Feb. 14, 2013

Prolor Biotech's hGH-CTP receives orphan drug designation in Europe

Feb. 14, 2013

Pediatric indication of Ixiaro approved in Europe

Feb. 12, 2013

EMA committee begins safety review of Diane-35 and generics

Feb. 11, 2013

EMA grants accelerated assessment to trametinib application

Feb. 8, 2013

EMA approves label extension for Abilify

Feb. 6, 2013

French ANSM to suspend marketing of Diane-35 and generics for acne

Jan. 31, 2013

Prosensa's Duchenne muscular dystrophy products achieve orphan drug status

Jan. 30, 2013

Novartis receives positive CHMP opinion for Ilaris in acute gouty arthritis

Jan. 22, 2013

EMA confirms recommendation to suspend nicotinic acid/laropiprant

Jan. 21, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...